Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

HotStockResearch Oct. 25 at 5:15 AM

$APVO stock is trading like a dead monkey

0 · Reply

_MANDALORIAN_ Oct. 24 at 10:54 PM

$APVO i am an extreme bear towards most of the current replay plays. When was APVO ever a play. What replay, what bio, what treasury, what dubai, what ai, what tech. None of the keywords used so far.. I know only a few that made cash out of this long so far. Phase 3 incoming. This is gonna top IXHL by a mile. But not a straight line. Anyway you do your trading as you know. The time has almost come (well 4 to 8 weeks top). Call me an idiot. I love to be that idiot you call, i love screenshot proof. Thank you and good luck, even if you are on the other side ❤️

1 · Reply

UnicornProfits Oct. 24 at 8:32 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $LASE $APVO $PBM $RAYA splits

0 · Reply

theBigDollarski Oct. 24 at 7:21 PM

$APVO Is Marvin going to tap the ATM once more or fall on the knife eventually??

0 · Reply

HotStockResearch Oct. 24 at 5:42 PM

$APVO Filthy dogshit

0 · Reply

HotStockResearch Oct. 24 at 2:39 PM

$APVO this is utter dog shit

0 · Reply

the_wulf Oct. 24 at 8:10 AM

$APVO They have guarantees that must be paid within a month or two, and to achieve that, the share price must be raised very high. Keep your shares and never sell them. The rise is very close.

0 · Reply

HotStockResearch Oct. 24 at 1:20 AM

$APVO this is dogshit

0 · Reply

HotStockResearch Oct. 23 at 9:32 PM

$APVO this looks dead as a door knob

0 · Reply

sharaf1402 Oct. 23 at 8:11 PM

$APVO Tomorrow maybe big party 🎉

0 · Reply

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Sep 16, 2025, 8:30 AM EDT - 5 weeks ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 4, 2025, 8:45 AM EDT - 7 weeks ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025, 8:05 AM EDT - 2 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025, 8:05 AM EDT - 2 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Jun 20, 2025, 11:30 AM EDT - 4 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 4 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 4 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 4 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 4 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 4 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 4 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 4 months ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 5 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 5 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 6 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 6 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 6 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 7 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 7 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 7 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 7 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 8 months ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 9 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 9 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 10 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 11 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 11 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 11 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 11 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 11 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 14, 2023, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

HotStockResearch Oct. 25 at 5:15 AM

$APVO stock is trading like a dead monkey

0 · Reply

_MANDALORIAN_ Oct. 24 at 10:54 PM

1 · Reply

UnicornProfits Oct. 24 at 8:32 PM

0 · Reply

theBigDollarski Oct. 24 at 7:21 PM

$APVO Is Marvin going to tap the ATM once more or fall on the knife eventually??

0 · Reply

HotStockResearch Oct. 24 at 5:42 PM

$APVO Filthy dogshit

0 · Reply

HotStockResearch Oct. 24 at 2:39 PM

$APVO this is utter dog shit

0 · Reply

the_wulf Oct. 24 at 8:10 AM

$APVO They have guarantees that must be paid within a month or two, and to achieve that, the share price must be raised very high. Keep your shares and never sell them. The rise is very close.

0 · Reply

HotStockResearch Oct. 24 at 1:20 AM

$APVO this is dogshit

0 · Reply

HotStockResearch Oct. 23 at 9:32 PM

$APVO this looks dead as a door knob

0 · Reply

sharaf1402 Oct. 23 at 8:11 PM

$APVO Tomorrow maybe big party 🎉

0 · Reply

Felixii Oct. 23 at 3:14 PM

$APVO it will squeez next week

0 · Reply

JBRUN Oct. 23 at 2:50 PM

$APVO

0 · Reply

Whales22 Oct. 23 at 6:03 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $ACRV $TOVX $APVO $DE Watchlist,

0 · Reply

SwingToProfit Oct. 23 at 4:25 AM

$APVO Opinion - All in on other stocks so won't be trading this onev but it does look interesting. Sometimes but not always there is a intra day pop when a stock drops this far and moving average lines cross. Guestimate is $3-$4.7 wick top if it does go. - Opiniin

0 · Reply